Summarize the mechanism of action of andexanet alfa.Review the dosing parameters for andexanet alfa.Identify the indications for the use of andexanet alfa.This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent to members of the interprofessional team to use andexanet alfa when factor Xa reversal is appropriate. Anticoagulation reversal is often a critical need when therapy does not work as planned and bleeding ensues. Andexanet alfa is a recombinant modified Factor Xa protein approved by the FDA in May 2018 to reverse apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Anticoagulant reversal for life-threatening bleeds.FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019.Inhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI), increasing tissue factor-initiated thrombin generation.Binds and sequesters factor Xa inhibitors.Dosage Forms: solution reconstituted, 100 mg per vialĪdult Dosing Determined by last dose, type of factor Xa inhibitor, and dose of inhibitorĤ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 4 mg/minute for up to 120 minutesĨ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 8 mg/minute for up to 120 minutes.Type: factor Xa inhibitor reversal, antidote.2.1 Determined by last dose, type of factor Xa inhibitor, and dose of inhibitor.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |